Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Serine incorporator 4 (SERINC4)
- Target
- SERINC4
- Molecular classification
- Membrane protein, Transporter/Carrier protein, Serine incorporator family member
01
Overview
Serine incorporator 4 (SERINC4) is a multi-pass transmembrane protein of the serine incorporator (SERINC) family, functioning primarily to incorporate the amino acid serine into membrane lipids, supporting biosynthesis of phosphatidylserine and sphingolipids[2][4][6]. SERINC4 participates in essential membrane biogenesis pathways and has a proposed role in the antiviral defense against retroviruses such as HIV, possibly operating as a restriction factor by modulating viral envelope protein conformation and inhibiting membrane fusion[2][7]. The gene displays differential expression across tissues and is implicated in certain cancers, congenital glycosylation disorders, and other conditions, though direct drug modulators are not currently described.
- Other names
- SERINC4FLJ40363
02
Mechanism of action
Notable for its antiviral activity, SERINC4 can inhibit viral entry and infectivity of HIV and other retroviruses, likely by interfering with membrane fusion and altering envelope glycoproteins. Its function does not appear to be directly modulated by small-molecule drugs at present.
03
Biological functions
Incorporation of L-serine into cell membranesBiosynthesis of serine-derived lipids (phosphatidylserine and sphingolipids)Involvement in metabolic pathways (e.g., metabolism, peptide chain elongation)
04
Disease associations
Cancer (aberrant expression in various tumors)Viral infection/antiviral response (SERINC proteins can restrict viruses such as HIV, MLV, and HBV; SERINC4 shows strong inhibitory effects against HIV)Congenital disorder of glycosylation, type IpDuane retraction syndromeOther: developmental (cleft lip/palate), nerve-related diseases (some evidence in seizure Parkinsonism, borderline personality)
05
Safety considerations
Therapeutic targeting may present challenges typically associated with membrane proteins, such as delivery and specificity
Beyond the preview
Go deeper on Serine incorporator 4 (SERINC4).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Serine incorporator 4 (SERINC4).